Welcome to our dedicated page for Nrx Pharmaceuticals SEC filings (Ticker: NRXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. NRx Pharmaceuticals is a Delaware-incorporated, clinical-stage biopharmaceutical company focused on NMDA-based therapies for central nervous system disorders, including suicidal depression, bipolar depression, chronic pain, and PTSD. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols NRXP and NRXPW, respectively, as reflected in multiple Form 8-K filings.
Through this page, readers can review Form 10-Q and related notifications such as Form 12b-25 (NT 10-Q), which explain timing of quarterly report submissions and provide context on financial reporting. Form 8-K filings document material events, including registered direct offerings of common stock, acquisitions and strategic interests executed through the HOPE Therapeutics subsidiary, changes in independent registered public accounting firms, and FDA-related developments that the company chooses to disclose under Regulation FD or Item 8.01 Other Events.
For a company like NRx Pharmaceuticals, which is advancing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), SEC filings can shed light on capital-raising activities, use of at-the-market offering programs, and the financial impact of building an interventional psychiatry clinic network. Filings related to acquisitions, such as Dura Medical, LLC and Cohen & Associates, include pro forma financial information and audited or unaudited financial statements that help illustrate how these clinic operations integrate into the consolidated company.
Stock Titan enhances access to these documents with real-time updates from EDGAR and AI-powered summaries that explain the key points of each filing in clear language. Users can quickly understand the significance of 8-K disclosures, accounting firm changes, and other regulatory items without reading every technical detail. This structure allows investors to monitor NRXP’s evolving financial condition, corporate transactions, and governance disclosures directly from its official SEC record.
NRx Pharmaceuticals, Inc. reported that its audit committee has appointed Weinberg & Company P.A. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg previously audited the financial statements of Dura Medical LLC, which was acquired by Hope Therapeutics, Inc., a subsidiary of NRx.
As part of this change, the audit committee dismissed Salberg & Company P.A. as the company’s independent auditor on or around November 24, 2025. Salberg’s audit reports on the December 31, 2024 and December 31, 2023 consolidated financial statements contained an explanatory paragraph about NRx’s ability to continue as a going concern, but no adverse opinions, disclaimers, or qualifications.
The company states there were no disagreements or reportable events with Salberg under SEC definitions during the past two fiscal years and through September 30, 2025. Salberg provided a letter to the SEC confirming its agreement with NRx’s description of the relationship and the change in auditors.
NRx Pharmaceuticals, Inc. filed an amended current report to add required financial information related to its acquisition of Dura Medical, LLC. The company previously reported the completion of this acquisition and is now providing Dura Medical’s standalone financial statements and combined pro forma financials.
The amendment includes audited financial statements of Dura Medical for the year ended December 31, 2024, unaudited financial statements as of and for the six months ended June 30, 2025, and unaudited pro forma combined financial statements showing NRx and Dura Medical on a combined basis. These materials are provided as exhibits and are incorporated by reference, while all other information from the original report remains unchanged.
NRx Pharmaceuticals (NRXP) reported a larger loss and ongoing financial strain for the nine months ended September 30, 2025, while advancing its drug pipeline and launching clinical operations. The company recorded a net loss of about
Cash and cash equivalents were
NRx Pharmaceuticals (NRXP) reported that its subsidiary, HOPE Therapeutics, completed the acquisition of a strategic minority interest in Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates on October 17, 2025. The deal was executed under a Membership Interest Purchase Agreement with customary representations, warranties, indemnification, and post‑closing adjustments.
In connection with the transaction, Dr. Rebecca Cohen was appointed Medical Director of HOPE Therapeutics, with employment terms that include financial incentives to establish and grow new sites of care owned or operated by HOPE Therapeutics. The company also furnished a related press release as Exhibit 99.1.
NRx Pharmaceuticals, Inc. announced on September 24, 2025 that the U.S. Food and Drug Administration granted a Suitability Petition for the strength the company proposed for its planned single‑patient, preservative‑free ketamine product, KETAFREE™. The filing explains that currently marketed ketamine is supplied in multi‑dose vials containing the toxic preservative Benzethonium Chloride, and the granted petition permits immediate re‑filing of the company’s Abbreviated New Drug Application for KETAFREE™. The item notes the press release is furnished as Exhibit 99.1 and clarifies this disclosure is furnished, not "filed," under Exchange Act liability provisions.
NRX Pharmaceuticals insider Jonathan C. Javitt, identified as Chairman and Chief Scientist and a 10% owner, reported a grant of 125,000 stock options on 04/09/2025. The options have an exercise price of $1.7297 and an expiration date shown as 04/09/2035. The filing notes that the options were granted under the issuer's 2021 Omnibus Incentive Plan and vest with one-third on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments, subject to continued service. Following the transaction, Javitt beneficially owns 125,000 underlying shares/options directly.
NRX Pharmaceuticals director Dennis McBride received an award of stock options. The Form 4 reports a grant dated 04/09/2025 of 25,000 stock options with an exercise price of $1.7297 per share. The options vest on 04/09/2026 subject to continued service and expire on 04/09/2035. The reported position following the grant is ownership of 25,000 underlying common shares through the options, held directly. The filing is signed by Dennis McBride on 09/10/2025 and lists his role as a director of NRX Pharmaceuticals (NRXP). This disclosure shows a standard equity compensation grant to an insider rather than an open-market purchase or sale.
Chaim Hurvitz, a director of NRX Pharmaceuticals, Inc. (NRXP), was granted 25,000 stock options on 04/09/2025 under the Issuer's 2021 Omnibus Incentive Plan. The options have an exercise price of $1.7297 per share, a ten-year term expiring on 04/09/2035, and vest on 04/09/2026 subject to continued service. Following the reported transaction the filing indicates Hurvitz beneficially owns 25,000 underlying shares through these options. The Form 4 is filed individually and is signed by the reporting person on 09/10/2025.
NRX Pharmaceuticals director Patrick Flynn was granted stock options to buy 50,000 shares of the company's common stock, with an exercise price of $1.7297. The options were granted on 04/09/2025, vest on 04/09/2026 contingent on continued service, and expire on 04/09/2035. The reported position after the grant shows beneficial ownership of the 50,000 underlying shares through the options. The Form 4 reflects a routine equity award to an insider under the issuer's 2021 Omnibus Incentive Plan.
NRx Pharmaceuticals reported that it recently raised an aggregate of approximately $8.8 million in gross proceeds from sales of common stock. The company clarified that this amount is comprised of gross proceeds from a registered direct common stock offering announced in August 2025 and from shares sold under its at-the-market (ATM) offering since the current fiscal quarter began on July 1, 2025. The company said these issuances included no warrants, repricing adjustments, or other variable rate features, and that the substantial majority of the proceeds were placed with experienced biotech investors. The disclosure notes the company will revert to reporting ATM gross proceeds in its quarterly reports and furnishes a related press release as an exhibit.